Loading organizations...
§ Private Profile · Maple Grove, MN, USA
Minimally invasive medical devices for structural heart disease, treating mitral and tricuspid regurgitation with AltaValve system.
4C Medical Technologies is a clinical-stage medical device developer based in Maple Grove, Minnesota, that creates minimally invasive therapies for structural heart disease. The company focuses on treating mitral and tricuspid regurgitation through its flagship AltaValve system, a transcatheter mitral valve replacement device designed to preserve the heart's native anatomy and left ventricle function. Operating with approximately 31 employees, the pre-revenue enterprise has secured at least $70 million in total venture capital financing to fund its clinical trials and regulatory approval processes. This capitalization includes a $35 million Series C funding round closed in 2022, which was led by strategic investor MicroPort Scientific Corporation. Under the leadership of Chief Executive Officer Saravana Kumar, the firm continues to advance its early feasibility studies for presentation at major scientific symposiums. 4C Medical Technologies was founded in 2015 by Jeffrey Chambers and Dr. JC Sun.
4C Medical Technologies has raised $71.0M across 4 funding rounds.
4C Medical Technologies has raised $71.0M in total across 4 funding rounds.
4C Medical Technologies has raised $71.0M across 4 funding rounds. Most recently, it raised $35.0M Series C in April 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 4, 2022 | $35M Series C | MicroPort CardioFlow Medtech Corporation | — | Announced |
| Dec 22, 2020 | $10M Venture Round | — | — | Announced |
| Sep 4, 2018 | $17M Series A | — | — | Announced |
| Jul 4, 2017 | $9M Venture Round | Anges Québec | — | Announced |
4C Medical Technologies has raised $71.0M in total across 4 funding rounds.
4C Medical Technologies's investors include MicroPort CardioFlow Medtech Corporation, Anges Québec.